Comparative Cost-Effectiveness of Tofacitinib With Continuing Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs for Active Rheumatoid Arthritis in South Korea.

So-Young HaYoon-Bo ShimMin-Young LeeBon-San KooJae-Hoon KimJa-Young JeonHyun-Jeong YooYoung-Joo KimJu-Young ShinMi-Hai Park

Published in: Rheumatology and therapy (2021)

Starting with tofacitinib and incorporating it into a csDMARDs treatment sequence is cost-effective compared to continuing csDMARDs alone in patients with RA.

Keyphrases

rheumatoid arthritis
disease activity
interstitial lung disease
ankylosing spondylitis
medical education
combination therapy
ulcerative colitis
amino acid